Azaya, Cytori deal

Cytori said it will acquire Azaya’s liposomal nanoparticle technology platform, including two cancer drugs: ATI-0918, a generic nanoparticle liposomal formulation of doxorubicin; and ATI-1123, a liposomal encapsulated docetaxel, which has completed Phase I testing. If the acquisition closes, Cytori plans to submit a regulatory application for ATI-0918 in the EU in early 2018...